Targets › CALCA
3 programs from 3 companies in 7 trials: 7 Phase 3; Neurology; next expected readout Nov 2026.
[Calcitonin]: Peptide hormone secreted by thyroid parafollicular (C) cells that acts as a high-affinity agonist of the calcitonin receptor/CALCR that primarily couples to Gs/adenylate cyclase signaling, resulting in activation of cAMP-dependent pathways, and can additionally mobilize intracellular calcium and activate ERK signaling. Acutely lowers blood calcium levels predominantly by inhibiting osteoclast-mediated…. (UniProt, P01258)
Open in Phaseline: the race on CALCA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Eli Lilly | Galcanezumab (LY2951742) Calcitonin gene-related peptide inhibitor | CALCA, CALCB | Phase 3 | Episodic Migraine; Chronic Migraine | Nov 2026 |
| H. Lundbeck | Eptinezumab Calcitonin gene-related peptide inhibitor | CALCA, CALCB | Phase 3 | Chronic Migraine in Children; Episodic Migraine; Migraine; Post Traumatic Headache | Mar 2027 |
| Oslo University Hospital | CGRP monoclonal antibody CGRP receptor antagonist monoclonal antibody | CALCA | Phase 3 | Migraine | Jan 2029 |
Episodic Migraine (2) Migraine (2) Chronic Migraine in Children (1) Post Traumatic Headache (1) Chronic Migraine (1)
antibody (2), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.